Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

Darzalex as monotherapy was investigated in two main studies involving multiple myeloma patients whose disease relapsed after, or was refractory to, at least two previous treatments, including a ...

Financial, family, and logistical challenges often lead patients to choose ongoing therapies over stem cell transplantation, ...

The good news, I guess, is that we have very many different treatment options for relapse refractory multiple myeloma, and some of that is considered in the background of what we do for patients with ...

Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

For patients newly diagnosed with multiple myeloma, optimal outcomes start with a clear set of goals. "The primary goals of initial treatment are straightforward: relieve symptoms like anemia ...

Multiple myeloma causes lytic or osteolytic lesions, which are areas of damage caused by cancerous plasma cells blocking normal bone growth. While painful, they can be managed. Multiple myeloma is ...

Signs and Symptoms That Occur With Multiple Myeloma As cancerous plasma cells multiply within the bone marrow, they reveal their presence in a number of ways. The main three tend to be: Bone Pain ...

Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone. The guidance recommends the ...